Polen Capital, an investment management company, released its fourth-quarter investor letter for “Polen 5Perspectives Small Growth Strategy”. A copy of the letter can be downloaded here. The Polen 5Perspectives Small Growth Composite Portfolio returned -1.3% gross and -1.5% net of fees in the fourth quarter of 2025, compared to a 1.2% return of the Russell 2000 Growth Index. Following double-digit returns in 2Q and 3Q, small caps concluded the year with a 1.2% return in 4Q. Biotech stood out as a major per ...

NEEDHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will present at TD Cowen’s 46th Annual Health Care Conference, being held on March 2-4, 2026 in Boston, MA. Presentation Details: Date: Tuesday, March 3, ...

NEEDHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will present at TD Cowen’s 46th Annual Health Care Conference, being held on March 2-4, 2026 in Boston, MA. Presentation Details: Date: Tuesday, March 3, ...

CORAL GABLES, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming Barclays 28th Annual Global Healthcare Conference on ...

BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president and chief executive officer, will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 9:50 a.m. ET. A live webcast of the event can be accessed under the ‘Events & ...

CONSHOHOCKEN, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 2:30 P.M. ET. The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events page. A replay of the webcast will be available after the event. About Madrigal PharmaceuticalsMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharm ...

Core Viewpoint - Kyverna Therapeutics has appointed Sravan K. Emany and Andrew Miller, Ph.D. to its Board of Directors, enhancing its leadership team as the company advances towards commercialization of its cell therapies for autoimmune diseases [1][3]. Group 1: Board Appointments - Sravan K. Emany will serve as the Audit Committee Chair, succeeding Dan Spiegelman, who has stepped down from the Board [2]. - Andrew Miller, Ph.D. is recognized for his extensive experience in clinical development and product approval, which will support Kyverna's growth [1][3]. Group 2: Leadership Experience - Sravan Emany has a strong background in financial leadership, currently serving as CFO of Beam Therapeutics, and has held significant roles in investment banking, including at Bank of America and Goldman Sachs [3][4]. - Dr. Andrew Miller was the Founder and President of R&D at Karuna Therapeutics, which was acquired by Bristol Myers Squibb for $14 billion in 2024, and has been recognized as one of Time Magazine's 100 Next Generation Leaders [4]. Group 3: Company Overview - Kyverna Therapeutics is focused on developing cell therapies for autoimmune diseases, with its lead candidate, miv-cel, showing potential to change treatment paradigms for B-cell-driven autoimmune diseases [5]. - The company is advancing its neuroimmunology franchise with completed and ongoing registrational trials for conditions such as stiff person syndrome and generalized myasthenia gravis [5].

VANCOUVER, Wash. and NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the fourth quarter and full year 2025 after market close on Tuesday, March 24, 2026. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) ...

Core Insights - Clene Inc. is focused on developing treatments for neurodegenerative diseases, particularly ALS, through its investigational drug CNM-Au8, with key regulatory and clinical milestones anticipated in 2026 [1][2] Financial Position - The company completed an oversubscribed registered direct offering of over $28 million in January 2026, providing sufficient cash to fund operations into the fourth quarter of 2026 [4][7] - Additional financing tranches totaling over $22 million are structured to align with NDA acceptance and FDA approval milestones, expected to support operations into 2027 [4] Regulatory Steps and Clinical Milestones - Clene has engaged with the FDA regarding CNM-Au8, with an in-person Type C meeting scheduled by the end of Q1 2026 to discuss data submitted in late 2025 [5][7] - The company plans to submit a New Drug Application (NDA) for CNM-Au8 via an accelerated regulatory pathway in Q2 2026, with potential FDA acceptance and PDUFA date issuance in the second half of 2026 [5][7] Clinical Data and Efficacy - CNM-Au8 has shown prolonged survival in ALS patients, with a median life expectancy of 2-4 years post-diagnosis, and demonstrated statistically significant reductions in mortality risk and clinical worsening [6][8] - The treatment has also shown favorable safety and tolerability, with no serious adverse events reported across over 1,000 patient years of treatment [9] Future Trials - A confirmatory Phase 3 RESTORE-ALS trial is planned to begin later in 2026 to further evaluate the survival benefit of CNM-Au8 [10] Broader Pipeline - CNM-Au8 is also being explored for potential benefits in multiple sclerosis (MS) and Parkinson's disease, with plans to finalize Phase 3 clinical trial designs for MS in 2026 [12]

ANN ARBOR, Mich., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report fourth quarter and full year 2025 financial results before the market opens on Tuesday, March 10, 2026. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours ...